Lentiviral Vector Purification Workflow for GMP-Grade Scale-Up
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant lentiviral vectors are not suitable for large-scale industrial production and do not meet GMP-grade standards due to high impurity levels and low yield, making them unsuitable for human use.
Innovation Solution
A method involving microfiltration, optional concentration, chromatography, and liquid exchange to purify recombinant lentiviral vectors, using specific chromatography resins like CAPTO™ Q and CAPTO™ ImpRes, to achieve high purity and compliance with GMP standards.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If ultracentrifugation is used to obtain lentiviral vectors, then the preparation process is simple, but the prepared lentiviral vector contains high levels of endotoxin, BSA, HCP or nucleic acid residues and cannot be used directly in the human body
Solution Approach 1:
The patent applies extraction by removing harmful impurities (endotoxin, BSA, HCP, nucleic acid residues) from the lentiviral vector preparation through a multi-step purification process involving chromatography resins and filtration, thereby eliminating the harmful factors while maintaining the simplicity of the overall process
Solution Approach 2:
The patent changes the purification parameters by using specific chromatography resins (Q Sepharose, IMAC) and adjusting pH, ionic strength, and filtration conditions to achieve high-purity lentiviral vectors suitable for human use while maintaining process simplicity
2Manufacturing precision
If conventional chromatographic purification methods are used, then purification is achieved, but the steps are complicated, yield is low and purity is insufficient to meet GMP-grade production requirements
Solution Approach 1:
The patent merges multiple purification functions into a streamlined process by combining chromatography steps (anion exchange, cation exchange, affinity chromatography) with microfiltration and concentration, achieving GMP-grade purity while reducing overall process complexity through integrated operations
Solution Approach 2:
The patent optimizes purification parameters including pH gradients, ionic strength, flow rates, and resin selection to achieve high purity with fewer steps, specifically using Q Sepharose for anion exchange and IMAC for cation exchange to meet GMP requirements efficiently
3Manufacturing precision
If conventional chromatographic purification methods are used, then purification is attempted, but the yield is low and the process cannot meet industrial large-scale production requirements
Solution Approach 1:
The patent segments the purification process into distinct modular steps (microfiltration, concentration, chromatography, buffer exchange) that can be independently optimized and scaled, thereby maintaining high purity while improving yield and enabling industrial large-scale production
Solution Approach 2:
The patent changes scale-up parameters by optimizing resin bed volumes, flow rates, and concentration factors to maintain high purity and yield simultaneously, enabling the process to meet both GMP-grade purity requirements and industrial production scalability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables efficient, large-scale production of high-purity recombinant lentiviral vectors with low impurities and endotoxin levels, suitable for pharmaceutical applications.
Implementation Method 1
carrying out a microfiltration treatment on the feed liquid to obtain a microfiltered filtrate
Implementation Method 2
purifying the filtrate obtained in the previous step by means of chromatography to obtain a crude pure product
Implementation Method 3
the chromatography is selected from anion chromatography, molecular exclusion chromatography and multimodal composite resin chromatography
Implementation Method 4
which can be obtained by ultracentrifugation or chromatographic purification
Data Source
AI summary
Provided is a method for large-scale preparation of a purified preparation of a recombinant lentiviral vector at the GMP grade. The method comprises: (a) providing raw material feed liquid to be purified that comprises recombinant viral vectors; (b) carrying out a microfiltration treatment on the feed liquid to obtain a microfiltered filtrate comprising the recombinant viral vectors; (c) optionally concentrating the filtrate to obtain a concentrated filtrate; (d) purifying the filtrate obtained in the previous step by means of chromatography to obtain a crude pure product comprising the recombinant viral vectors; and (e) subjecting the crude pure product obtained in the previous step to liquid exchange and elaborate purification to obtain the purified recombinant viral vectors.